Adequacy of phosphodiesterase inhibitor in prevention and treatment of LPS induced organ failure in BALB/c mice


  • Ammara Khan Department of Pharmacology, Therapeutics, Nawaz Sharif Medical College, University of Gujrat. Hafiz Hayat Campus. Gujrat, Pakistan
  • Ayesha Afzal Department of Pharmacology, Therapeutics, Wah Medical College, Wah Cantt, Wah, Pakistan
  • Hammad A. Butt Department of Pharmacology and Therapeutics, Combined Military Hospital Kharian, Pakistan
  • Akbar Waheed Department of Pharmacology and Therapeutics, Islamic International Medical College, Riphah International University, Islamabad, Pakistan



Endotoxin, Gram negative sepsis, Hepatotoxicity, LPS, Pentoxifylline, Phosphodiesterase inhibitor


Background: Even though with immense improvement and extensive understanding of pathophysiology of sepsis induced organ failure and affected population, it continues to put hundreds of people worldwide to eternal sleep due to lack of targeted therapy. Newer treatment modalities is the dire need of time. The present study was aimed to ascertain the adequacy of phosphodiesterases inhibitor - pentoxifylline (75mg/kg i.p) in endotoxin/LPS induced hepatotoxicity in BALB/c mice.

Methods: The number of animals in each group was six. Endotoxin/lipopolysaccharides induced hepatotoxicity was reproduced in mice by giving lipopolysaccharide of serotype E. coli intraperitoneally. To ascertain the Preventive role, pentoxifylline was administered forehand LPS injection whereas therapeutic potential adjuged via post LPS delivering. The extent of liver damage was evaluated through serum alanine aminotransferases (ALT) and aspartate aminotransferase (AST) estimation along with histopathological examination of liver tissue.

Results: Results set forth that serum ALT, AST levels and histological alteration abated considerably (p ≤0.05) both in animals subjected to pentoxifylline pre and post-treatment.

Conclusions: Pentoxifylline set up promising results in endotoxin induced hepatotoxicity and can be used therapeutic adjuncts to conventional treatment strategies in sepsis induced liver failure.


Jawad I, Lukšić I, Rafnsson SB. Assessing available information on the burden of sepsis: global estimates of incidence, prevalence and mortality. J Global Health. 2012 Jun;2(1).

Brun-Buisson C, Meshaka P, Pinton P, Vallet B. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intens Care Med, 2004;30:580-8.

Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Critical Care Med. 2003 Mar 1;31(3):834-40.

Yalaz M, Çetin H, Akisu M, Aydemir S, Tunger A, Kultursay N. Neonatal nosocomial sepsis in a level-III NICU: evaluation of the causative agents and antimicrobial susceptibilities. Turkish J Pediatr. 2006 Jan 1;48(1):13.

Anwer SK, Mustafa S, Pariyani S, Ashraf S, Taufiq KM. Neonatal sepsis: an etiological study. JPMA. The J Pakistan Med Assoc. 2000 Mar;50(3):91-4.

Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010 Mar 19;140(6):805-20.

Yamamoto M, Takeda K. Current views of toll-like receptor signaling pathways. Gastroenterol Res Practice. 2010;2010.

Ulevitch RJ, Tobias PS. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol. 1995;13(1):437-57.

Nesseler N, Launey Y, Aninat C, Morel F, Mallédant Y, Seguin P. Clinical review: the liver in sepsis. Critical Care. 2012 Oct;16(5):235.

Frampton JE, Brogden RN. Pentoxifylline (oxpentifylline). Drugs Aging. 1995 Dec 1;7(6):480-503.

Samlaska CP, Winfield EA. Pentoxifylline. J Am Acad Dermatol. 1994 Apr 1;30(4):603-21.

Kreth S, Ledderose C, Luchting B, Weis F, Thiel M. Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways. Shock. 2010 Jul 1;34(1):10-6.

Deree J, Martins JO, Melbostad H, Loomis WH, Coimbra R. Insights into the regulation of TNF-a production in human mononuclear cells: the effects of non-specific phosphodiesterase inhibition. Clinics. 2008;63(3):321-8.

Galea E, Feinstein DL. Regulation of the expression of the inflammatory nitric oxide synthase (NOS2) by cyclic AMP. FASEB J. 1999 Dec;13(15):2125-37.

Chong YH, Shin YJ, Suh YH. Cyclic AMP Inhibition of Tumor Necrosis Factor α Production Induced by Amyloidogenic C-Terminal Peptide of Alzheimer's Amyloid Precursor Protein in Macrophages: Involvement of Multiple Intracellular Pathways and Cyclic AMP Response Element Binding Protein. Molecular Pharmacol. 2003 Mar 1;63(3):690-8.

Wen AY, Sakamoto KM, Miller LS. The role of the transcription factor CREB in immune function. J Immunol. 2010 Dec 1;185(11):6413-9.

Kreth S, Ledderose C, Kaufmann I, Groeger G, Thiel M. Differential expression of 5′-UTR splice variants of the adenosine A2A receptor gene in human granulocytes: identification, characterization, and functional impact on activation. FASEB J. 2008 Sep;22(9):3276-86.

Thiel M, Caldwell CC, Sitkovsky MV. The critical role of adenosine A2A receptors in downregulation of inflammation and immunity in the pathogenesis of infectious diseases. Microbes Infection. 2003 May 1;5(6):515-26.

Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 2001 Dec;414(6866):916.

Voisin L, Breuillé D, Ruot B, Rallière C, Rambourdin F, Dalle M, et al. Cytokine modulation by PX differently affects specific acute phase proteins during sepsis in rats. Am J Physiol Regulatory Integrative Comparative Physiol. 1998 Nov 1;275(5):R1412-9.

Wang W, Zolty E, Falk S, Basava V, Reznikov L, Schrier R. Pentoxifylline protects against endotoxin-induced acute renal failure in mice. Am J Physiol Renal Physiol. 2006 Nov;291(5):F1090-5.

Oliveira-Júnior IS, Brunialti MK, Koh IH, Junqueira VB, Salomão R. Effect of pentoxifylline on lung inflammation and gas exchange in a sepsis-induced acute lung injury model. Brazilian J Med Biol Res. 2006 Nov;39(11):1455-63.

Sneed RA, Buchweitz JP, Jean PA, Ganey PE. Pentoxifylline attenuates bacterial lipopolysaccharide-induced enhancement of allyl alcohol hepatotoxicity. Toxicological Sciences. 2000 Jul 1;56(1):203-10.

Wei SD, Li JZ, Liu ZJ, Chen Q, Chen Y, Chen M, et al. 2Dexamethasone attenuates lipopolysaccharide‐induced liver injury by down regulating glucocorticoid‐induced tumor necrosis factor receptor ligand in Kupffer cells. Hepatol Res. 2011;41(10):989-9.

Belikoff B, Buras JA. A practical approach to animal models of sepsis. InSourcebook of models for biomedical research. Humana Press. 2008:473-82.

González-Renovato ED, Alatorre-Jiménez M, Bitzer-Quintero OK, Sánchez-Luna S, Flores-Alvarado LJ, Romero-Dávalos R, et al. Effect of Nutrisim© on endotoxic shock induced by lipopolysaccharide from Escherichia coli: 0111: b4 in rats: structural study of liver, kidney and lung. J Clin Exp Pathol. 2013;4(1):1-5.

Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatol. 2000 Jan;31(1):241-6.

Schmöcker C, Weylandt KH, Kahlke L, Wang J, Lobeck H, Tiegs G, et al. Omega‐3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines. Hepatol. 2007 Apr 1;45(4):864-9.

Shah AA, Hasan F, Hameed A. Study on the prevalence of enterobacteriacae in hospital acquired and community acquired infections. Pak J Med Res. 2002;41(1):4-8.

Fink MP. Animal models of sepsis. Virulence. 2014 Jan 1;5(1):143-53.

Buness A, Roth A, Herrmann A, Schmitz O, Kamp H, Busch K, et al. Identification of metabolites, clinical chemistry markers and transcripts associated with hepatotoxicity. PloS One. 2014 May 16;9(5):e97249.

Klopfleisch R. Multiparametric and semiquantitative scoring systems for the evaluation of mouse model histopathology-a systematic review. BMC Vet Res. 2013 Dec;9(1):123.

Nemzek JA, Hugunin K, Opp MR. Modeling sepsis in the laboratory: merging sound science with animal well-being. Comparative Med. 2008 Apr 16;58(2):120-8.

Tukov FF, Luyendyk JP, Ganey PE, Roth RA. The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury. Toxicol Sci. 2007 Aug 13;100(1):267-80.

Lowes DA, Webster NR, Murphy MP, Galley HF. Antioxidants that protect mitochondria reduce interleukin-6 and oxidative stress, improve mitochondrial function, and reduce biochemical markers of organ dysfunction in a rat model of acute sepsis. Br J Anaesthesia. 2013 Feb 4;110(3):472-80.

Semmler J, Gebert U, Eisenhut T, Moeller J, Schönharting MM, Allera A, et al. Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity. Immunol. 1993 Apr;78(4):520.

Coimbra R, Porcides RD, Melbostad H, Loomis W, Tobar M, Hoyt DB, et al. Nonspecific phosphodiesterase inhibition attenuates liver injury in acute endotoxemia. Surg Infections. 2005 Mar 1;6(1):73-85.

Coimbra R, Melbostad H, Loomis W, Porcides RD, Wolf P, Tobar M, et al. LPS-induced acute lung injury is attenuated by phosphodiesterase inhibition: effects on proinflammatory mediators, metalloproteinases, NF-κB, and ICAM-1 expression. J Trauma Acute Care Surg. 2006 Jan 1;60(1):115-25.

Heller S, Weber K, Heller A, Urbaschek R, Koch T. Pentoxifylline improves bacterial clearance during hemorrhage and endotoxemia. Crit Care Med. 1999;27:756-63.

Azevedo ÍM, Pinheiro LAM, de Araújo C, Torres MMSAS, Grossi TRM, Filho AI, Rego ACM, et al. 2010. Effects of pentoxifylline in the treatment of abdominal sepsis in rats. J Surg Clin Res. 2010;33-45.




How to Cite

Khan, A., Afzal, A., Butt, H. A., & Waheed, A. (2019). Adequacy of phosphodiesterase inhibitor in prevention and treatment of LPS induced organ failure in BALB/c mice. International Journal of Basic & Clinical Pharmacology, 8(3), 549–556.



Original Research Articles